Phase II, proof-of-concept, sham-controlled, double-masked trial evaluating the safety, tolerability, and efficacy of KVD001 in Subjects with Diabetic Macular Edema
Phase of Trial: Phase II
Latest Information Update: 05 Jan 2018
At a glance
- Drugs KVD 001 (Primary)
- Indications Diabetic macular oedema
- Focus Proof of concept; Therapeutic Use
- 05 Jan 2018 According to a KalVista Pharmaceuticals media release, top-line results are expected in the second half of 2019.
- 05 Jan 2018 Status changed from planning to recruiting, as reported in a KalVista Pharmaceuticals media release.
- 22 Nov 2016 According to a KalVista Pharmaceuticals media release, this study is expected to start in 2017.